MAGEA3 and testicular cancer: Increasing evidence has accumulated that shows that DAC alone or combined with other epigenetic reagents such as histone deacetylase inhibitors can specifically improve the expression of the testicular cancer antigens NY-ESO-1; MAGE-1, MAGE-2, MAGE-3; and GAGE39 in tumor cells but not in normal epithelial cells.45,46 Furthermore, the de novo expression of NY-ESO-1 induced by DAC was found to be persistent.